AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Biocardia Inc (NASDAQ:BCDA)
0.88 USD
+0.085 10.678%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.7951 |
|---|---|
| Change | +0.085 10.678% |
| 52 W H/L (in USD) | 3.200/1.000 |
| EBITDA (in USD) | -8.254M |
| PE Ratio | -- |
| Volume | 1111453 |
| Diluted Eps TTM | -1.23 |
| Total Assets (in USD) | 3.413M |
|---|---|
| Total Liabilities (in USD) | 2.518M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 2.496M |
| Market Cap (in USD) | 13.676 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -4.962M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Employees: 17
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Peter A. Altman Ph.D. | CEO, Pres & Director | 1967 |
| 2. | Mr. David McClung | Chief Financial Officer | 1963 |
| 3. | Mr. Edward M. Gillis | Sr. VP of Devices | 1962 |
| 4. | Dr. Ian McNiece Ph.D. | Chief Scientific Officer | 1954 |
| 5. | Dr. Sujith Shetty | Chief Medical Officer and VP of Clinical & Regulatory | NA |
| 6. | Dr. Peter A. Altman Ph.D. | CEO, President & Director | 1967 |
| 7. | Mr. Edward M. Gillis | Senior Vice President of Devices | 1962 |
| 8. | Dr. Sujith Shetty MBBS | Chief Medical Officer and VP of Clinical & Regulatory | NA |
| 9. | Ms. Miranda Peto Benvenuti | Investor Relations Executive | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -8.228M | -7.946M | -11.571M | -11.907M | -12.623M |
| Minority Interest | - | - | - | - | - |
| Net Income | -8.228M | -7.946M | -11.571M | -11.913M | -12.621M |
| Selling General Administrative | 3.316M | 3.672M | 4.395M | 4.419M | 5.087M |
| Gross Profit | -0.505M | -4.329M | -7.249M | -10.549M | 1.015M |
| Reconciled Depreciation | 0.024M | 0.067M | 0.084M | 0.082M | 0.06M |
| Ebit | -8.278M | -8.001M | -11.644M | -11.983M | -12.63M |
| Ebitda | -7.773M | -7.934M | -11.56M | -11.901M | -12.563M |
| Depreciation And Amortization | 0.505M | 0.067M | 0.084M | 0.082M | 0.067M |
| Operating Income | -8.278M | -8.001M | -11.644M | -11.901M | -12.63M |
| Other Operating Expenses | 8.278M | 8.059M | 12.121M | 13.253M | 13.645M |
| Interest Expense | - | - | - | 0.006M | 0.009M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | 0.009M |
| Net Interest Income | - | - | - | - | 0.009M |
| Income Tax Expense | - | -7.946M | 0.243M | 0.006M | -0.002M |
| Total Revenue | 0M | 0.058M | 0.477M | 1.352M | 1.015M |
| Total Operating Expenses | 7.773M | 3.672M | 4.395M | 13.253M | 13.645M |
| Cost Of Revenue | 0.505M | 4.387M | 7.726M | 11.901M | 0M |
| Total Other Income Expense Net | 0.05M | 0.055M | 0.073M | -0.006M | 0.007M |
| Net Income From Continuing Ops | -8.228M | -7.946M | -11.571M | -11.907M | -12.623M |
| Net Income Applicable To Common Shares | - | - | - | -11.907M | -12.623M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 3.413M | 3.724M | 2.987M | 9.793M | 15.718M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.216M | 0.251M | 0.295M | 0.501M | 0.462M |
| Total Liab | 2.518M | 2.887M | 4.59M | 4.901M | 5.343M |
| Total Stockholder Equity | 0.895M | 0.837M | -1.603M | 4.892M | 10.375M |
| Other Current Liab | 1.349M | 1.019M | 1.824M | 1.622M | 1.435M |
| Common Stock | 0.011M | 0.005M | 0.024M | 0.02M | 0.017M |
| Capital Stock | 0.011M | 0.005M | 0.024M | 0.02M | 0.017M |
| Retained Earnings | -168.349M | -160.121M | -152.175M | -140.604M | -128.697M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.171M | 0.172M |
| Cash | 2.496M | 2.371M | 1.103M | 7.363M | 12.872M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.432M | 2.321M | 3.608M | 3.585M | 3.712M |
| Current Deferred Revenue | - | 0.532M | 0.561M | 0.965M | 1.533M |
| Net Debt | -1.968M | -1.42M | 0.212M | -5.732M | -11.004M |
| Short Term Debt | 0.442M | 0.385M | 0.333M | 0.315M | 0.237M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.528M | 0.951M | 1.315M | 1.631M | 1.868M |
| Other Stockholder Equity | 169.233M | 160.953M | 150.548M | 145.476M | 139.055M |
| Property Plant Equipment | - | - | - | 1.758M | 2.065M |
| Total Current Assets | 2.732M | 2.622M | 1.461M | 7.864M | 13.481M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.02M | 0M | 0.063M | 0.201M | 0.147M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | -0.201M | - |
| Accounts Payable | 0.641M | 0.385M | 0.89M | 0.683M | 0.507M |
| Accumulated Other Comprehensive Income | - | - | - | - | - |
| Non Currrent Assets Other | 0.171M | 0.171M | 0.171M | 0.171M | 0.172M |
| Non Current Assets Total | 0.681M | 1.102M | 1.526M | 1.929M | 2.237M |
| Capital Lease Obligations | 0.528M | 0.951M | 1.315M | 1.631M | 1.868M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -0.006M | -0.012M | -0.07M | -0.116M |
| Total Cashflows From Investing Activities | -0.007M | -0.006M | -0.012M | -0.07M | -0.116M |
| Total Cash From Financing Activities | 7.568M | 9.3M | 3.726M | 5.122M | 1.947M |
| Net Income | -8.228M | -7.946M | -11.571M | -11.907M | -12.623M |
| Change In Cash | 0.125M | 1.268M | -6.26M | -5.509M | -8.535M |
| Begin Period Cash Flow | 2.371M | 1.103M | 7.363M | 12.872M | 21.407M |
| End Period Cash Flow | 2.496M | 2.371M | 1.103M | 7.363M | 12.872M |
| Total Cash From Operating Activities | -7.436M | -8.026M | -9.974M | -10.561M | -10.366M |
| Depreciation | 0.024M | 0.067M | 0.084M | 0.082M | 0.06M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 0.507M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -0.197M | -1.252M | -0.662M | -0.418M | -0.054M |
| Capital Expenditures | 0.007M | 0.006M | 0.012M | 0.07M | 0.116M |
| Change In Working Capital | -0.143M | -1.217M | 0.129M | -0.214M | 0.517M |
| Other Non Cash Items | 0.481M | 0.329M | 0.354M | 0.295M | 0.019M |
| Free Cash Flow | -7.443M | -8.032M | -9.986M | -10.631M | -10.482M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Series Total Market Index | 3 months ago | 8599 |
| 2. | Spartan Total Market Index Pool G | 3 months ago | 6424 |
| 3. | Fidelity Total Market Index | 3 months ago | 3237 |
| 4. | Fidelity Nasdaq Composite Index | 3 months ago | 964 |
| 5. | Northern Trust Extended Eq Market Idx | 8 months ago | 668 |
| 6. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 668 |
| 7. | NT Ext Equity Mkt Idx Fd - NL | 2 months ago | 567 |
| 8. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 months ago | 444 |
| 9. | Vanguard U.S. Eq Idx £ Acc | 2 months ago | 268 |
| 10. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 2 months ago | 264 |
| 11. | Spartan Extended Market Index Pool F | 3 months ago | 173 |
| 12. | State St US Extended Mkt Indx NL Cl C | 3 months ago | 100 |
| 13. | Blackstone Alternative Multi-Strategy I | 8 months ago | 47 |
| 14. | Northern Trust Wilshire 5000 | 8 months ago | 46 |
| 15. | NT US Market Cap Idx Fd - L | 2 months ago | 46 |
| 16. | Aptus Impact Series Growth | 5 months ago | 41 |
| 17. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 69023 |
| 18. | Abante Quant Value FI | 4 months ago | 57366 |
| 19. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 55568 |
| 20. | Fidelity Extended Market Index | 3 months ago | 49705 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | UBS Group AG | 8 months ago | 10740 |
| 2. | Vanguard Group Inc | 5 months ago | 135561 |
| 3. | CM Management, LLC | 5 months ago | 130000 |
| 4. | Citadel Advisors Llc | 5 months ago | 94247 |
| 5. | Geode Capital Management, LLC | 5 months ago | 66003 |
| 6. | DRW Securities, LLC | 5 months ago | 57607 |
| 7. | Susquehanna International Group, LLP | 5 months ago | 38809 |
| 8. | Brown Advisory Holdings Inc | 5 months ago | 35538 |
| 9. | Wealth Enhancement Advisory Services, LLC | 5 months ago | 20000 |
| 10. | Commonwealth Equity Services Inc | 5 months ago | 18283 |
| 11. | XTX Topco Ltd | 5 months ago | 16290 |
| 12. | GSA Capital Partners LLP | 5 months ago | 11303 |
| 13. | Two Sigma Investments LLC | 5 months ago | 11229 |
| 14. | Tower Research Capital LLC | 5 months ago | 3294 |
| 15. | Morgan Stanley - Brokerage Accounts | 8 months ago | 3105 |
| 16. | Pingora Partners LLC | 5 months ago | 3036 |
| 17. | Citigroup Inc | 8 months ago | 833 |
| 18. | Bank of America Corp | 8 months ago | 421 |
| 19. | Global Retirement Partners, LLC. | 5 months ago | 411 |
| 20. | SBI Securities Co Ltd | 5 months ago | 6 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...